Six-Year Outcomes in Subjects with Polypoidal Choroidal Vasculopathy in the PLANET Study

Abstract Introduction The PLANET study demonstrated that intravitreal aflibercept 2 mg injection (IAI) monotherapy was non-inferior to IAI with rescue photodynamic therapy (PDT) for polypoidal choroidal vasculopathy (PCV) at 2 years. This follow-up study assessed the long-term outcomes 6 years after...

Szczegółowa specyfikacja

Opis bibliograficzny

Główni autorzy:	Kelvin Yi Chong Teo, Young Hee Yoon, Shigeru Honda, Kyu Hyung Park, Hidenori Takahashi, Ryuichi Ideta, Tetsuju Sekiryu, Akira Hirata, Akira Obana, Ryusaburo Mori, Shih-Jen Chen, Caroline Chee, James G. Wong, Timothy Y. Y. Lai, Ian Wong, Nick Fung, Won Ki Lee, Hiroko Terasaki, Shih-Chou Chen, Takafumi Miyatani, Tomohiro Iida, Ryo Obata, Tobias Machewitz, Sergio Leal, Chui ming Gemmy Cheung
Format:	Artigo
Język:	Inglês
Wydane:	Adis, Springer Healthcare 2026-03-01
Seria:	Ophthalmology and Therapy
Hasła przedmiotowe:	Polypoidal choroidal vasculopathy (PCV) Long-term outcomes Aflibercept Anti-vascular endothelial growth factor (VEGF) therapies Best-corrected visual acuity (BCVA) Photodynamic therapy (PDT)
Dostęp online:	https://doi.org/10.1007/s40123-026-01366-5
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!